15 completed, 3 terminated, 1 no longer available. 13 Phase 1, 3 Phase 2, 2 Phase 3.
By phase and status
Follow pimodivir: new trials by email Literature Review of pimodivir trials Research Report on pimodivir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study of Orally Administered Pimodivir in Adult Participants With Renal Impairment Pimodivir - Kidney Failure, Chronic Phase 1 Terminated Janssen-Cilag International NV 29 2019-07-02 2025-02-03 A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment Pimodivir - Hepatic Impairment Phase 1 Completed Janssen-Cilag International NV 42 2019-05-28 2025-02-03 A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults Pimodivir, Cyclosporine - Healthy Phase 1 Completed Janssen-Cilag International NV 18 2018-12-06 2019-04-29 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Pimodivir 600 mg, Placebo, SOC Treatment - Influenza A Phase 3 Terminated Janssen Research & Development, LLC 553 2018-01-21 2025-02-04 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Pimodivir 600 mg, Placebo, SOC Treatment - Influenza A Phase 3 Terminated Janssen Research & Development, LLC 334 2018-01-03 2025-02-04 A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-63623872/Oseltamivir Fixed-dose Combination Tablet and Single Agent Concept Formulations of JNJ-63623872 Compared to Their Respective Reference Formulation in Healthy Adult Participants JNJ-63623872, Oseltamivir - Healthy Phase 1 Completed Janssen-Cilag International NV 45 2017-02-14 2017-05-25 Safety, Tolerability, Pharmacokinetic and Absolute Bioavailability Study of JNJ-63623872 Administered as an Intravenous Infusion and a 600-Milligram (mg) Oral Dose in Healthy Adults JNJ-63623872, Placebo - Healthy Phase 1 Completed Janssen-Cilag International NV 66 2016-08-08 2018-01-30 A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872 AL-794, Oseltamivir, Digoxin - Influenza in Humans Phase 1 Completed Alios Biopharma Inc. 68 2016-07-31 2025-02-03 A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants JNJ-63623872 2400 milligram (mg), JNJ-63623872 3000 mg, JNJ-63623872 - Healthy Phase 1 Completed Janssen Research & Development, LLC 66 2016-01-01 2025-02-03 A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection JNJ-63623872, Placebo, Oseltamivir - Influenza A Virus Phase 2 Completed Janssen Research & Development, LLC 102 2015-12-11 2020-03-27 A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone Ethinylestradiol, Norethindrone, JNJ-63623872 - Healthy Phase 1 Completed Janssen Research & Development, LLC 18 2015-12-01 2016-06-06 A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation JNJ-63623872 300 milligram (mg), JNJ-63623872 600 mg - Influenza A Virus Phase 1 Completed Janssen Research & Development, LLC 90 2015-12-01 2025-02-03 A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants Pitavastatin, JNJ-63623872 - Healthy Phase 1 Completed Janssen Research & Development, LLC 14 2015-11-01 2016-01-27 Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants JNJ-63623872 - Healthy Phase 1 Completed Janssen Cilag N.V./S.A. 6 2015-05-11 2017-07-02 A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-63623872 in Healthy Japanese Adult Participants JNJ-63623872 (300 mg), JNJ-63623872 (600 mg), JNJ-63623872 (1200 mg) - Healthy Phase 1 Completed Janssen Infectious Diseases BVBA 24 2015-05-01 2015-09-22 Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg - Influenza A Phase 2 Completed Janssen Research & Development, LLC 292 2014-12-11 2025-02-04 A Study to Assess the Drug-Drug Interaction Between VX-787 and Oseltamivir VX-787, Oseltamivir, Placebo - Healthy Phase 1 Completed Janssen Infectious Diseases BVBA 38 2014-07-01 2014-11-04 A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus VX-787, Placebo - Influenza Virus Phase 2 Completed Vertex Pharmaceuticals Incorporated 140 2012-03-01 2016-09-02 Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection Pimodivir - H7N9 Subtype of Influenza A Virus No longer available Janssen Research & Development, LLC 2020-10-28
Conditions studied Influenza, Human (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1)
Sponsors Janssen Research & Development, LLC (9) · Janssen-Cilag International NV (5) · Janssen Infectious Diseases BVBA (2) · Alios Biopharma Inc. (1) · Janssen Cilag N.V./S.A. (1) · Vertex Pharmaceuticals Incorporated (1)
Countries Belgium (12) · Germany (6) · United Kingdom (5) · Canada (4) · Netherlands (4) · United States (4) · Australia (3) · Brazil (3) · Bulgaria (3) · France (3) · Latvia (3) · Malaysia (3) · New Zealand (3) · South Africa (3) · Spain (3)
Top investigators Adeep Puri (1) · Jose Trevejo, MD, PhD (1)
Results publications PMID 39172627 , PMID 30428049 , PMID 32604406 , PMID 33248473
NIH funding 2015 (7), 2018 (3), 2014 (2), 2016 (2), 2017 (2)